Which has better earnings and valuation, TGTX or BHVN?

TG Therapeutics has higher revenue and earnings than Biohaven. Biohaven is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TG Therapeutics $799.54M 10.32 $447.18M $2.74 19.68 Biohaven N/A N/A -$738.82M -$4.64 N/A

Is TGTX or BHVN more profitable?

TG Therapeutics has a net margin of 55.22% compared to Biohaven's net margin of 0.00%. TG Therapeutics' return on equity of 73.49% beat Biohaven's return on equity. Company Net Margins Return on Equity Return on Assets TG Therapeutics 55.22% 73.49% 34.14% Biohaven N/A -1,328.94% -138.27%

Does the media favor TGTX or BHVN?

In the previous week, Biohaven had 17 more articles in the media than TG Therapeutics. MarketBeat recorded 25 mentions for Biohaven and 8 mentions for TG Therapeutics. TG Therapeutics' average media sentiment score of 1.19 beat Biohaven's score of 0.74 indicating that TG Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TG Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biohaven 12 Very Positive mention(s) 4 Positive mention(s) 7 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, BHVN or IBRX?

ImmunityBio has higher revenue and earnings than Biohaven. ImmunityBio is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biohaven N/A N/A -$738.82M -$4.64 N/A ImmunityBio $165.79M 51.46 -$351.40M -$0.97 N/A

Is BHVN or IBRX more profitable?

Biohaven has a net margin of 0.00% compared to ImmunityBio's net margin of -598.55%. ImmunityBio's return on equity of 0.00% beat Biohaven's return on equity. Company Net Margins Return on Equity Return on Assets Biohaven N/A -1,328.94% -138.27% ImmunityBio -598.55% N/A -51.65%

Does the media prefer BHVN or IBRX?

In the previous week, Biohaven had 16 more articles in the media than ImmunityBio. MarketBeat recorded 25 mentions for Biohaven and 9 mentions for ImmunityBio. Biohaven's average media sentiment score of 0.74 beat ImmunityBio's score of 0.61 indicating that Biohaven is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biohaven 12 Very Positive mention(s) 4 Positive mention(s) 7 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive ImmunityBio 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, BHVN or ALKS?

Alkermes has higher revenue and earnings than Biohaven. Biohaven is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biohaven N/A N/A -$738.82M -$4.64 N/A Alkermes $1.48B 5.39 $241.66M $0.38 124.76

Is BHVN or ALKS more profitable?

Alkermes has a net margin of 3.96% compared to Biohaven's net margin of 0.00%. Alkermes' return on equity of 4.15% beat Biohaven's return on equity. Company Net Margins Return on Equity Return on Assets Biohaven N/A -1,328.94% -138.27% Alkermes 3.96% 4.15% 2.19%

Does the media refer more to BHVN or ALKS?

In the previous week, Biohaven had 18 more articles in the media than Alkermes. MarketBeat recorded 25 mentions for Biohaven and 7 mentions for Alkermes. Biohaven's average media sentiment score of 0.74 beat Alkermes' score of 0.63 indicating that Biohaven is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biohaven 12 Very Positive mention(s) 4 Positive mention(s) 7 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Alkermes 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to BHVN or RYTM?

In the previous week, Biohaven had 11 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 25 mentions for Biohaven and 14 mentions for Rhythm Pharmaceuticals. Rhythm Pharmaceuticals' average media sentiment score of 1.44 beat Biohaven's score of 0.74 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biohaven 12 Very Positive mention(s) 4 Positive mention(s) 7 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Rhythm Pharmaceuticals 11 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, BHVN or ORKA?

Oruka Therapeutics is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biohaven N/A N/A -$738.82M -$4.64 N/A Oruka Therapeutics N/A N/A -$105.43M -$2.03 N/A

Is BHVN or ORKA more profitable?

Oruka Therapeutics' return on equity of -21.65% beat Biohaven's return on equity. Company Net Margins Return on Equity Return on Assets Biohaven N/A -1,328.94% -138.27% Oruka Therapeutics N/A -21.65% -20.88%

Does the media favor BHVN or ORKA?

In the previous week, Biohaven had 13 more articles in the media than Oruka Therapeutics. MarketBeat recorded 25 mentions for Biohaven and 12 mentions for Oruka Therapeutics. Oruka Therapeutics' average media sentiment score of 1.45 beat Biohaven's score of 0.74 indicating that Oruka Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biohaven 12 Very Positive mention(s) 4 Positive mention(s) 7 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Oruka Therapeutics 9 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Biohaven (BHVN) Competitors

$15.41 -0.71 (-4.40%)

As of 08/28/2026 03:58 PM Eastern

Compare

BHVN vs. TGTX, IBRX, ALKS, RYTM, and ORKA

Should you buy Biohaven stock or one of its competitors? Biohaven's main competitors and comparable companies include TG Therapeutics (TGTX), ImmunityBio (IBRX), Alkermes (ALKS), Rhythm Pharmaceuticals (RYTM), and Oruka Therapeutics (ORKA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Biohaven compare to TG Therapeutics?

TG Therapeutics (NASDAQ:TGTX) and Biohaven (NYSE:BHVN) are both mid-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, analyst recommendations, institutional ownership, risk and valuation.

TG Therapeutics has a net margin of 55.22% compared to Biohaven's net margin of 0.00%. TG Therapeutics' return on equity of 73.49% beat Biohaven's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TG Therapeutics	55.22%	73.49%	34.14%
Biohaven	N/A	-1,328.94%	-138.27%

58.6% of TG Therapeutics shares are held by institutional investors. Comparatively, 88.8% of Biohaven shares are held by institutional investors. 8.9% of TG Therapeutics shares are held by insiders. Comparatively, 13.8% of Biohaven shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

TG Therapeutics has higher revenue and earnings than Biohaven. Biohaven is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TG Therapeutics	$799.54M	10.32	$447.18M	$2.74	19.68
Biohaven	N/A	N/A	-$738.82M	-$4.64	N/A

In the previous week, Biohaven had 17 more articles in the media than TG Therapeutics. MarketBeat recorded 25 mentions for Biohaven and 8 mentions for TG Therapeutics. TG Therapeutics' average media sentiment score of 1.19 beat Biohaven's score of 0.74 indicating that TG Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TG Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Biohaven	12 Very Positive mention(s)	4 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

TG Therapeutics currently has a consensus target price of $63.00, suggesting a potential upside of 16.82%. Biohaven has a consensus target price of $18.94, suggesting a potential upside of 22.89%. Given Biohaven's stronger consensus rating and higher possible upside, analysts clearly believe Biohaven is more favorable than TG Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TG Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44
Biohaven	2 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.65

TG Therapeutics has a beta of 1.62, indicating that its stock price is 62% more volatile than the broader market. Comparatively, Biohaven has a beta of 1.26, indicating that its stock price is 26% more volatile than the broader market.

Summary

TG Therapeutics beats Biohaven on 9 of the 16 factors compared between the two stocks.

How does Biohaven compare to ImmunityBio?

Biohaven (NYSE:BHVN) and ImmunityBio (NASDAQ:IBRX) are both mid-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, risk, institutional ownership, analyst recommendations, earnings and dividends.

Biohaven has a net margin of 0.00% compared to ImmunityBio's net margin of -598.55%. ImmunityBio's return on equity of 0.00% beat Biohaven's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biohaven	N/A	-1,328.94%	-138.27%
ImmunityBio	-598.55%	N/A	-51.65%

In the previous week, Biohaven had 16 more articles in the media than ImmunityBio. MarketBeat recorded 25 mentions for Biohaven and 9 mentions for ImmunityBio. Biohaven's average media sentiment score of 0.74 beat ImmunityBio's score of 0.61 indicating that Biohaven is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biohaven	12 Very Positive mention(s)	4 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
ImmunityBio	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

ImmunityBio has higher revenue and earnings than Biohaven. ImmunityBio is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biohaven	N/A	N/A	-$738.82M	-$4.64	N/A
ImmunityBio	$165.79M	51.46	-$351.40M	-$0.97	N/A

Biohaven currently has a consensus price target of $18.94, suggesting a potential upside of 22.89%. ImmunityBio has a consensus price target of $14.20, suggesting a potential upside of 76.40%. Given ImmunityBio's stronger consensus rating and higher probable upside, analysts clearly believe ImmunityBio is more favorable than Biohaven.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biohaven	2 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.65
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Biohaven has a beta of 1.26, indicating that its stock price is 26% more volatile than the broader market. Comparatively, ImmunityBio has a beta of 0.03, indicating that its stock price is 97% less volatile than the broader market.

88.8% of Biohaven shares are owned by institutional investors. Comparatively, 8.6% of ImmunityBio shares are owned by institutional investors. 13.8% of Biohaven shares are owned by insiders. Comparatively, 66.1% of ImmunityBio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Biohaven and ImmunityBio tied by winning 8 of the 16 factors compared between the two stocks.

How does Biohaven compare to Alkermes?

Biohaven (NYSE:BHVN) and Alkermes (NASDAQ:ALKS) are both mid-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and media sentiment.

Alkermes has higher revenue and earnings than Biohaven. Biohaven is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biohaven	N/A	N/A	-$738.82M	-$4.64	N/A
Alkermes	$1.48B	5.39	$241.66M	$0.38	124.76

Biohaven has a beta of 1.26, suggesting that its stock price is 26% more volatile than the broader market. Comparatively, Alkermes has a beta of 0.34, suggesting that its stock price is 66% less volatile than the broader market.

Biohaven currently has a consensus target price of $18.94, suggesting a potential upside of 22.89%. Alkermes has a consensus target price of $54.56, suggesting a potential upside of 15.09%. Given Biohaven's higher possible upside, equities analysts plainly believe Biohaven is more favorable than Alkermes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biohaven	2 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.65
Alkermes	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.72

88.8% of Biohaven shares are held by institutional investors. Comparatively, 95.2% of Alkermes shares are held by institutional investors. 13.8% of Biohaven shares are held by insiders. Comparatively, 4.6% of Alkermes shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Biohaven had 18 more articles in the media than Alkermes. MarketBeat recorded 25 mentions for Biohaven and 7 mentions for Alkermes. Biohaven's average media sentiment score of 0.74 beat Alkermes' score of 0.63 indicating that Biohaven is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biohaven	12 Very Positive mention(s)	4 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Alkermes	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Alkermes has a net margin of 3.96% compared to Biohaven's net margin of 0.00%. Alkermes' return on equity of 4.15% beat Biohaven's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biohaven	N/A	-1,328.94%	-138.27%
Alkermes	3.96%	4.15%	2.19%

Summary

Alkermes beats Biohaven on 10 of the 16 factors compared between the two stocks.

How does Biohaven compare to Rhythm Pharmaceuticals?

Biohaven (NYSE:BHVN) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation, risk and media sentiment.

Biohaven has a net margin of 0.00% compared to Rhythm Pharmaceuticals' net margin of -85.59%. Rhythm Pharmaceuticals' return on equity of -159.87% beat Biohaven's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biohaven	N/A	-1,328.94%	-138.27%
Rhythm Pharmaceuticals	-85.59%	-159.87%	-44.00%

Biohaven presently has a consensus target price of $18.94, suggesting a potential upside of 22.89%. Rhythm Pharmaceuticals has a consensus target price of $141.12, suggesting a potential upside of 31.68%. Given Rhythm Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Rhythm Pharmaceuticals is more favorable than Biohaven.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biohaven	2 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.65
Rhythm Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.74

88.8% of Biohaven shares are held by institutional investors. 13.8% of Biohaven shares are held by company insiders. Comparatively, 5.9% of Rhythm Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Rhythm Pharmaceuticals has higher revenue and earnings than Biohaven. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biohaven	N/A	N/A	-$738.82M	-$4.64	N/A
Rhythm Pharmaceuticals	$239.92M	30.61	-$196.54M	-$3.11	N/A

In the previous week, Biohaven had 11 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 25 mentions for Biohaven and 14 mentions for Rhythm Pharmaceuticals. Rhythm Pharmaceuticals' average media sentiment score of 1.44 beat Biohaven's score of 0.74 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biohaven	12 Very Positive mention(s)	4 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Rhythm Pharmaceuticals	11 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Biohaven has a beta of 1.26, meaning that its stock price is 26% more volatile than the broader market. Comparatively, Rhythm Pharmaceuticals has a beta of 1.92, meaning that its stock price is 92% more volatile than the broader market.

Summary

Rhythm Pharmaceuticals beats Biohaven on 10 of the 16 factors compared between the two stocks.

How does Biohaven compare to Oruka Therapeutics?

Biohaven (NYSE:BHVN) and Oruka Therapeutics (NASDAQ:ORKA) are both mid-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.

88.8% of Biohaven shares are owned by institutional investors. Comparatively, 56.4% of Oruka Therapeutics shares are owned by institutional investors. 13.8% of Biohaven shares are owned by insiders. Comparatively, 23.5% of Oruka Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Biohaven has a beta of 1.26, indicating that its stock price is 26% more volatile than the broader market. Comparatively, Oruka Therapeutics has a beta of -0.34, indicating that its stock price is 134% less volatile than the broader market.

Oruka Therapeutics' return on equity of -21.65% beat Biohaven's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biohaven	N/A	-1,328.94%	-138.27%
Oruka Therapeutics	N/A	-21.65%	-20.88%

In the previous week, Biohaven had 13 more articles in the media than Oruka Therapeutics. MarketBeat recorded 25 mentions for Biohaven and 12 mentions for Oruka Therapeutics. Oruka Therapeutics' average media sentiment score of 1.45 beat Biohaven's score of 0.74 indicating that Oruka Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biohaven	12 Very Positive mention(s)	4 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Oruka Therapeutics	9 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Biohaven presently has a consensus target price of $18.94, suggesting a potential upside of 22.89%. Oruka Therapeutics has a consensus target price of $134.30, suggesting a potential upside of 47.36%. Given Oruka Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Oruka Therapeutics is more favorable than Biohaven.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biohaven	2 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.65
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

Oruka Therapeutics is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biohaven	N/A	N/A	-$738.82M	-$4.64	N/A
Oruka Therapeutics	N/A	N/A	-$105.43M	-$2.03	N/A

Summary

Oruka Therapeutics beats Biohaven on 9 of the 14 factors compared between the two stocks.

Get Biohaven News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BHVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BHVN vs. The Competition

Export

Metric	Biohaven	Biotechnology Industry	Healthcare Sector	NYSE Exchange
Market Cap	$2.33B	$3.93B	$7.20B	$24.17B
Dividend Yield	N/A	3.61%	2.54%	3.71%
P/E Ratio	-3.32	11.62	273.16	29.99
Price / Sales	N/A	1,396.16	640.19	96.22
Price / Cash	N/A	106.39	76.74	32.24
Price / Book	192.63	16.53	12.98	7.67
Net Income	-$738.82M	-$22.80M	$3.48B	$1.07B
7 Day Performance	10.78%	-0.31%	0.13%	-0.32%
1 Month Performance	11.42%	9.80%	7.08%	1.84%
1 Year Performance	0.36%	55.66%	24.67%	13.37%

Biohaven Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BHVN Biohaven	2.7474 of 5 stars	$15.41 -4.4%	$18.94 +22.9%	+0.4%	$2.33B	N/A	N/A	239	News Coverage Analyst Forecast
TGTX TG Therapeutics	3.4374 of 5 stars	$56.01 +3.2%	$63.00 +12.5%	+83.9%	$8.31B	$616.29M	20.44	290	Positive News
IBRX ImmunityBio	2.2866 of 5 stars	$7.58 -2.7%	$14.20 +87.3%	+244.0%	$8.26B	$113.29M	N/A	590
ALKS Alkermes	2.2159 of 5 stars	$48.87 +1.1%	$54.56 +11.6%	+63.7%	$8.11B	$1.67B	128.61	2,050
RYTM Rhythm Pharmaceuticals	2.8725 of 5 stars	$111.44 +1.3%	$142.44 +27.8%	+3.9%	$7.54B	$189.76M	N/A	140	Positive News Analyst Forecast Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:BHVN) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Biohaven (BHVN) Competitors

BHVN vs. TGTX, IBRX, ALKS, RYTM, and ORKA

How does Biohaven compare to TG Therapeutics?

Summary

How does Biohaven compare to ImmunityBio?

Summary

How does Biohaven compare to Alkermes?

Summary

How does Biohaven compare to Rhythm Pharmaceuticals?

Summary

How does Biohaven compare to Oruka Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BHVN vs. The Competition

Biohaven Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Biohaven (BHVN) Competitors

BHVN vs. TGTX, IBRX, ALKS, RYTM, and ORKA

How does Biohaven compare to TG Therapeutics?

Is TGTX or BHVN more profitable?

Do insiders and institutionals have more ownership in TGTX or BHVN?

Which has better earnings and valuation, TGTX or BHVN?

Does the media favor TGTX or BHVN?

Do analysts recommend TGTX or BHVN?

Which has more volatility and risk, TGTX or BHVN?

Summary

How does Biohaven compare to ImmunityBio?

Is BHVN or IBRX more profitable?

Does the media prefer BHVN or IBRX?

Which has stronger earnings and valuation, BHVN or IBRX?

Do analysts rate BHVN or IBRX?

Which has more risk & volatility, BHVN or IBRX?

Do institutionals and insiders hold more shares of BHVN or IBRX?

Summary

How does Biohaven compare to Alkermes?

Which has better earnings and valuation, BHVN or ALKS?

Which has more volatility & risk, BHVN or ALKS?

Do analysts prefer BHVN or ALKS?

Do institutionals and insiders hold more shares of BHVN or ALKS?

Does the media refer more to BHVN or ALKS?

Is BHVN or ALKS more profitable?

Summary

How does Biohaven compare to Rhythm Pharmaceuticals?

Is BHVN or RYTM more profitable?

Do analysts recommend BHVN or RYTM?

Do institutionals & insiders hold more shares of BHVN or RYTM?

Which has preferable earnings & valuation, BHVN or RYTM?

Does the media refer more to BHVN or RYTM?

Which has more volatility & risk, BHVN or RYTM?

Summary

How does Biohaven compare to Oruka Therapeutics?

Do institutionals and insiders hold more shares of BHVN or ORKA?

Which has more volatility & risk, BHVN or ORKA?

Is BHVN or ORKA more profitable?

Does the media favor BHVN or ORKA?

Do analysts rate BHVN or ORKA?

Which has preferable earnings and valuation, BHVN or ORKA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BHVN vs. The Competition

Biohaven Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools